<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724410</url>
  </required_header>
  <id_info>
    <org_study_id>08-10-13B</org_study_id>
    <nct_id>NCT02724410</nct_id>
  </id_info>
  <brief_title>Role of Intravenous Versus Home Oral Antibiotics in Perforated Appendicitis</brief_title>
  <official_title>Home Intravenous Versus Oral Antibiotics Following Appendectomy for Perforated Appendicitis in Children, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of a single-agent home intravenous (IV) versus oral antibiotic therapy&#xD;
      on complication rates and resource utilization following appendectomy for perforated&#xD;
      appendicitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Appendicitis is the most common cause of abdominal pain requiring emergent surgical&#xD;
      intervention in children and approximately one third of patients present with perforation.&#xD;
      Perforated appendicitis has been demonstrated to have a significant impact on patients and&#xD;
      families due to the prolonged hospitalization, high complication rates, and tremendous&#xD;
      economic burden from treatment. The most significant complication following operative&#xD;
      treatment of perforated appendicitis is intra-abdominal abscess, which develops in&#xD;
      approximately 20% of children following appendectomy in recent literature. Due to this&#xD;
      frequent and morbid complication, continued research has been driven at determining the most&#xD;
      efficacious and cost-effective postoperative antibiotic treatment regimen to reduce&#xD;
      post-operative abscess. As postoperative abscess rates following appendectomy for perforated&#xD;
      appendicitis remain high, the primary aim of this study was to evaluate a new postoperative&#xD;
      antibiotic treatment regimen based on single daily dosing ertapenem while inpatient with&#xD;
      randomization into ten day completion course of home antibiotics with IV ertapenem versus&#xD;
      oral amoxicillin/clavulanate. The hypothesis is that the ertapenem based regimen will offer&#xD;
      reduced rates of postoperative abscess, with no major difference between completion courses&#xD;
      of home IV versus oral antibiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative intrabdominal abscess rate</measure>
    <time_frame>thirty days after appendectomy</time_frame>
    <description>development of intrabdominal abscess following appendectomy in each treatment arm</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Perforated Appendicitis</condition>
  <arm_group>
    <arm_group_label>home intravenous ertapenem and PICC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages &lt;13; age 13 or greater, then 1 gm daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>home oral amoxicillin-clavulanate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>home intravenous ertapenem</intervention_name>
    <description>see arm description</description>
    <arm_group_label>home intravenous ertapenem and PICC</arm_group_label>
    <other_name>Invanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>home oral amoxicillin-clavulanate</intervention_name>
    <description>see arm description</description>
    <arm_group_label>home oral amoxicillin-clavulanate</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>peripheral inserted central Catheter</intervention_name>
    <description>All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.</description>
    <arm_group_label>home intravenous ertapenem and PICC</arm_group_label>
    <other_name>PICC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 4-17 years of age with perforated acute appendicitis diagnosed at time of&#xD;
             appendectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a known severe allergy to penicillin (anaphylaxis), prior severe side&#xD;
             effects from ertapenem or amoxicillin-clavulanate, pregnancy, or previous drainage&#xD;
             procedure for abscess and/or fluid collection related to appendicitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Heniford, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Heatlhcare System</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Todd Heniford</investigator_full_name>
    <investigator_title>Professor of Surgery, Chief of Division of Minimally Invasive Surgery</investigator_title>
  </responsible_party>
  <keyword>appendectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Appendicitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

